In vitro mesengenic potential of human umbilical cord blood-derived mesenchymal stem cells

Gang, Eun Ji; Hong, Seung Hyun; Jeong, Ju Ah; Hwang, Soo Han; Kim, Seong Whan; Yang, Ii Ho; Ahn, Chiyoung; Han, Hoon; Kim, Hoeon

doi:10.1016/j.bbrc.2004.06.111

Cited by 116 publications

(90 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Six full-term UCB units, each containing about 80 mm of blood, were processed as previously described [24][25][26]. For the isolation of MSCs, MNCs were plated at a density of 1 × 10 6 cells per cm 2 and allowed to adhere to culture flasks for 5 days.…”

Section: Cell Growth and Total Rna Isolationmentioning

confidence: 99%

Differential Gene Expression Profiling of Human Umbilical Cord Blood–Derived Mesenchymal Stem Cells by DNA Microarray

Jeong¹,

Hong²,

Gang³

et al. 2005

STEM CELLS

Self Cite

104

View full text Add to dashboard Cite

Mesenchymal stem cells (MSCs) retain both self-renewal and multilineage differentiation capabilities. Despite wide therapeutic potential, many aspects of human MSCs, particularly the molecular parameters to define the stemness, remain largely unknown. Using high-density oligonucleotide microarrays, we obtained the differential gene expression profile between a fraction of mononuclear cells of human umbilical cord blood (UCB) and its MSC subpopulation. Of particular interest was a subset of 47 genes preferentially expressed at 50-fold or higher in MSCs, which could be regarded as a molecular foundation of human MSCs. This subset contains numerous genes encoding collagens, other extracellular matrix or related proteins, cytokines or growth factors, and cytoskeleton-associated proteins but very few genes for membrane and nuclear proteins. In addition, a direct comparison of this microarray-generated transcriptome with the published serial analysis of gene expression data suggests that a molecular context of UCB-derived MSCs is more or less similar to that of bone marrow-derived cells. Altogether, our results will provide a basis for studies on molecular mechanisms controlling core properties of human MSCs. Stem Cells 2005;23:584-593

show abstract

Section: Cell Growth and Total Rna Isolationmentioning

confidence: 99%

Differential Gene Expression Profiling of Human Umbilical Cord Blood–Derived Mesenchymal Stem Cells by DNA Microarray

Jeong¹,

Hong²,

Gang³

et al. 2005

STEM CELLS

Self Cite

104

View full text Add to dashboard Cite

show abstract

“…Several studies indicate that UCB-derived MSCs (UCB-MSC) are similar to stem cells from bone marrow with respect to cell characteristics and multilineage differentiation potential (12)(13)(14)(15). In a previous study, we isolated multipotent UCB-MSCs that have the capacity to differentiate into several mesodermal tissues (bone, cartilage, tendon, muscle, and adipose), endodermal tissue (hepatocyte), and ectodermal tissue (neurons; refs.…”

Section: Introductionmentioning

confidence: 99%

Gene Therapy Using TRAIL-Secreting Human Umbilical Cord Blood–Derived Mesenchymal Stem Cells against Intracranial Glioma

Kim¹,

Lim²,

Park³

et al. 2008

Cancer Research

260

229

View full text Add to dashboard Cite

Adenovirus-mediated gene therapies against brain tumors have been limited by the difficulty in tracking glioma cells infiltrating the brain parenchyma. Human umbilical cord blood-derived mesenchymal stem cells (UCB-MSC) are particularly attractive cells for clinical use in cell-based therapies. In the present study, we evaluated the tumor targeting properties and antitumor effects of UCB-MSCs as gene delivery vehicles for glioma therapy. We efficiently engineered UCB-MSCs to deliver a secretable trimeric form of tumor necrosis factor-related apoptosis-inducing ligand (stTRAIL) via adenoviral transduction mediated by cellpermeable peptides. We then confirmed the migratory capacity of engineered UCB-MSCs toward tumor cells by an in vitro migration assay and by in vivo injection of UCB-MSCs into the tumor mass or the opposite hemisphere of established human glioma in nude mice. Moreover, in vitro coculture, experiments on Transwell plates, and in vivo survival experiments showed that MSC-based stTRAIL gene delivery has more therapeutic efficacy compared with direct injection of adenovirus encoding the stTRAIL gene into a tumor mass. In vivo efficacy experiments showed that intratumoral injection of engineered UCB-MSCs (MSCs-stTRAIL) significantly inhibited tumor growth and prolonged the survival of glioma-bearing mice compared with controls. These results suggest that human UCB-MSCs have potential use as effective delivery vehicles for therapeutic genes in the treatment of intracranial glioma. [Cancer Res 2008;68(23):9614-23]

show abstract

“…9 The ability to separate a significant number of adult MSC from other sources, such as cord blood (CB) and peripheral blood (PB), is controversial. [10][11][12][13][14] The isolation of a high number of potent MSC sets the basis for new methods for tissue regeneration and cell therapy. Nevertheless, the procedure of BM extraction is traumatic and the amount of material extracted is limited.…”

Section: Introductionmentioning

confidence: 99%

Isolation of mesenchymal stem cells from G-CSF-mobilized human peripheral blood using fibrin microbeads

Kassis

Zangi

Rivkin

et al. 2006

Bone Marrow Transplant

226

168

View full text Add to dashboard Cite

Adult mesenchymal stem cells (MSC) that are able to differentiate into various mesenchymal cell types are typically isolated from bone marrow, but their significant presence in human peripheral blood (PB) is controversial. Fibrin microbeads (FMB) that bind matrix-dependent cells were used to isolate MSC from the mononuclear fraction of mobilized PB of adult healthy human donors treated with a granulocyte colony-stimulating factor. Isolation by plastic adherence resulted in a negligible number of MSC in all samples tested, whereas FMBbased isolation yielded spindle-shaped cell samples that could further expand on plastic or on FMB in eight out of the 11 samples. The yield of these cells at days 17-18 after the harvest was B0.5% of the initial cell number. The isolated cells were grown on plastic and characterized by FACS analysis and immunohistochemistry for specific markers. Following culturing and first passage, the FMBisolated cells stained positive for mesenchymal stromal cell markers CD90 and CD105, expressed vimentin and fibronectin and were negative for hematopoietic markers CD45 and CD34. These cells could differentiate into osteoblasts, adipocytes and chondrocytes. This study indicates that FMB may have special advantage in isolating MSC from sources such as mobilized PB, where the number of such cells is scarce.

show abstract

In vitro mesengenic potential of human umbilical cord blood-derived mesenchymal stem cells

Cited by 116 publications

References 23 publications

Differential Gene Expression Profiling of Human Umbilical Cord Blood–Derived Mesenchymal Stem Cells by DNA Microarray

Differential Gene Expression Profiling of Human Umbilical Cord Blood–Derived Mesenchymal Stem Cells by DNA Microarray

Gene Therapy Using TRAIL-Secreting Human Umbilical Cord Blood–Derived Mesenchymal Stem Cells against Intracranial Glioma

Isolation of mesenchymal stem cells from G-CSF-mobilized human peripheral blood using fibrin microbeads

Contact Info

Product

Resources

About